Endo, Inc. (OTCQX: NDOI) announced the launch of ADRENALIN® (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag, with product shipments beginning the week of May 19, 2025. This new concentration joins Endo's existing line of ready-to-use epinephrine products, which remain the first FDA-approved and only commercially available manufacturer-prepared epinephrine premixed intravenous (IV) bags on the market.
The expanded product line addresses critical needs in hospital settings where healthcare providers face increasing workflow challenges. "Hospital pharmacists and healthcare providers are working harder than ever, and we are committed to supporting them with ready-to-use medicines that help reduce complexity and streamline operations so they can focus on what matters most—patient care," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions and Generics.
Key Clinical Benefits and Features
The ADRENALIN® premixed bag offers several advantages for clinical settings:
- No compounding or preparation required, saving valuable time for pharmacy staff
- Single-port IV tubing design to reduce the risk of inadvertent mixture
- Extended 24-month shelf life at room temperature, improving inventory management
ADRENALIN® is indicated specifically to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock, a life-threatening condition requiring prompt intervention.
Streamlining Hospital Operations
The ADRENALIN® premixed bag is part of Endo Injectable Solutions' TruDelivery® product line and platform. These ready-to-use products offer significant operational benefits for hospitals by eliminating preparation steps before patient administration.
The streamlined approach may provide multiple advantages:
- Reduced waste and associated costs
- Optimized workflow and convenience for healthcare staff
- Decreased risk of preparation errors, enhancing patient safety
"With this new ADRENALIN® premixed bag concentration, plus the additional concentrations in our pipeline, we are proud to offer options and choice through our TruDelivery® portfolio," Sims added.
Expanding Product Portfolio
Endo's epinephrine product line now includes multiple formulations to meet varying clinical needs:
- New 8 mg/250 mL premixed bag
- Existing 4 mg/250 mL premixed bag
- Planned 5 mg/250 mL and 10 mg/250 mL concentrations
- ADRENALIN® (epinephrine injection, USP) in 1 mL single-dose and 30 mL multi-dose vials
Safety Considerations
Healthcare providers should be aware of important safety information when administering ADRENALIN®. Key warnings include the risk of hypertension, pulmonary edema, cardiac arrhythmias, and tissue necrosis if extravasation occurs.
Common adverse reactions to systemically administered epinephrine include headache, anxiety, restlessness, tremor, dizziness, sweating, palpitations, and respiratory difficulties. More serious complications such as arrhythmias and cerebral hemorrhage can occur in some cases.
Careful monitoring is essential, particularly for patients receiving certain medications that may interact with epinephrine, including MAO inhibitors, beta blockers, and tricyclic antidepressants. Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally.
Market Impact
As the only manufacturer offering FDA-approved premixed epinephrine IV bags, Endo's expanded product line represents a significant advancement in critical care medication delivery. The company's focus on ready-to-use formulations aligns with industry trends toward reducing medication preparation steps and enhancing safety in high-stress clinical environments.
The introduction of multiple concentrations provides clinicians with more precise dosing options for patients with septic shock, potentially improving treatment outcomes while reducing preparation burden on hospital staff.
